BPIFB4 Circulating Levels and Its Prognostic Relevance in COVID-19. (16th August 2021)

• Record Type: Journal Article
• Authors: Ciaglia, Elena; Lopardo, Valentina; Montella, Francesco; Sellitto, Carmine; Manzo, Valentina; De Bellis, Emanuela; Iannaccone, Teresa; Franci, Gianluigi; Zannella, Carla; Pagliano, Pasquale; Di Pietro, Paola; Carrizzo, Albino; Vecchione, Carmine; Conti, Valeria; Filippelli, Amelia; Puca, Annibale Alessandro
• Editors: Le Couteur, David
• Is Part Of: Journals of gerontology. Volume 76:Number 10(2021)
• Page Start: 1775
• Page End: 1783
• Publication Date: 2021-08-16
• Subjects: Immunity function -- Longevity -- Plasma -- SARS-CoV-2; Geriatrics -- Periodicals; Gerontology -- Periodicals; 618.97
• DOI: 10.1093/gerona/glab208
• Languages: English
• ISSNs: 1079-5006

Abstract

Abstract: Aging and comorbidities make individuals at greatest risk of COVID-19 serious illness and mortality due to senescence-related events and deleterious inflammation. Long-living individuals (LLIs) are less susceptible to inflammation and develop more resiliency to COVID-19. As demonstrated, LLIs are characterized by high circulating levels of BPIFB4, a protein involved in homeostatic response to inflammatory stimuli. Also, LLIs show enrichment of homozygous genotype for the minor alleles of a 4 missense single-nucleotide polymorphism haplotype (longevity-associated variant [LAV]) in BPIFB4, able to counteract progression of diseases in animal models. Thus, the present study was designed to assess the presence and significance of BPIFB4 level in COVID-19 patients and the potential therapeutic use of LAV-BPIFB4 in fighting COVID-19. BPIFB4 plasma concentration was found significantly higher in LLIs compared to old healthy controls while it significantly decreased in 64 COVID-19 patients. Further, the drop in BPIFB4 values correlated with disease severity. Accordingly to the LAV-BPIFB4 immunomodulatory role, while lysates of SARS-CoV-2-infected cells induced an inflammatory response in healthy peripheral blood mononuclear cells in vitro, the co-treatment with recombinant protein (rh) LAV-BPIFB4 resulted in a protective and self-limiting reaction, culminating in the downregulation of CD69 activating-marker for T cells (both TCD4+ and TCD8+) and in MCP-1 reduction. On the contrary, rhLAV-BPIFB4 induced a rapid increase in IL-18 and IL-1b levels, shown largely protective during the early stages of the virus infection. This evidence, along with the ability of rhLAV-BPIFB4 to counteract the cytotoxicity induced by SARS-CoV-2 lysate in selected target cell lines, corroborates BPIFB4 prognostic value and open new therapeutic possibilities in more vulnerable people.